3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 3
2
Phase 1
2
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
145
Neoplasm Metastasis
16
Advanced Breast Cancer
9
Neoplasms
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Fulvestrant
3
Alpelisib
3
parsaclisib
2
Paclitaxel
2
Irinotecan
2
Cetuximab
2
Carboplatin
2
tanezumab
1
talazoparib
1
sotorasib
1
serabelisib
1
sapanisertib
1
ruxolitinib
1
olaparib
1
niraparib
1
liposomal doxorubicin
1
inavolisib
1
dapagliflozin
1
ceralasertib
1
binimetinib
1
berzosertib
1
avelumab
1
Vemurafenib
1
Topotecan
1
Taxes
1
SF 1126
1
Oxaliplatin
1
Lomustine
1
Leuprolide
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Hereditary Sensory and Autonomic Neuropathies
×
Fulvestrant
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled